Sharyn Baker

Image
Sharyn Baker

Sharyn Baker, PharmD, PhD

Title
Professor & Chair
Secondary Title
Gertrude Parker Heer Chair in Cancer Research, Professor of Pharmaceutics and Hematology, Chair, Pharmaceutics and Pharmaceutical Chemistry
Unit / Department / Division
Pharmaceutics and Pharmaceutical Chemistry
Address
Biomedical Research Tower
Email Address
Phone Number

Professional Interests

Professional Interests

Dr. Baker’s cancer-relevant research interests broadly cover translational and clinical pharmacology of anti-cancer agents. Recently, her laboratory has focused on the preclinical development of anti-cancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine kinase inhibitor (TKI) drug combinations. Dr. Baker’s research interests include developmental therapeutics for AML, clinical pharmacology of tyrosine kinase inhibitors, variability in anti-cancer drug disposition and investigational anti-cancer drug development.

Education

  • PhD, 2004, Erasmus University, The Netherlands
  • PharmD, 1991, University of California at San Francisco, Pharmacy
  • BA, 1986, Pacific Lutheran University, Biology

Honors

  • 2017: ASCPT Clinical and Translational Science Award
  • 2016: Developmental Therapeutics (DT) study section, National Cancer Institute, chartered member
  • 2009-2011: Editorial Board Member, Journal of Clinical Oncology
  • 2008-2014: Xenobiotic and Nutrient Disposition and Action (XNDA) study section, National Institutes of Health, ad hoc reviewer
  • 2008-present: Member, American Society of Hematology
  • 2006-present: Special Emphasis Panel/Scientific Review Group (various), National Institutes of Health, reviewer
  • 2006-2009: Chair, Hematologic and Neoplastic Diseases Scientific Section, American Society for Clinical Pharmacology and Therapeutics
  • 2004–2008: Pharmacology Co-Chair, Developmental Therapeutics Committee, Eastern Cooperative Oncology Group
  • 2004-present: Member, American Society of Clinical Pharmacology and Therapeutics
  • 1993-present: Member, American Association for Cancer Research
  • 1997-present: Member, American Society of Clinical Oncology

Journal Articles

  • Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:43-51.
  • Van Oosterwijk JG, Buelow DR, Drenberg CD, Vasilyeva A, Li L, Shi L, Wang YD, Finkelstein D, Shurtleff SA, Janke LJ, Pounds S, Rubnitz JE, Inaba H, Pabla N, Baker SD. Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest. 2018 Jan 02;128(1):369-380.
  • Jeon JY, Sparreboom A, Baker SD. Kinase Inhibitors: The Reality Behind the Success. Clin Pharmacol Ther. 2017 Nov;102(5):726-730.
  • Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, Pappo AS, Jeha S, Pui CH, Relling MV. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. Cancer. 2017 Sep 15;123(18):3602-3608.
  • Jarusiewicz JA, Jeon JY, Connelly MC, Chen Y, Yang L, Baker SD, Guy RK. Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. ACS Omega. 2017 May 31;2(5):1985-2009.
  • Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A. OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 04 15;77(8):2102-2111.
  • Drenberg CD, Buelow DR, Pounds SB, Wang YD, Finkelstein D, Rahija RJ, Shurtleff SA, Rubnitz JE, Inaba H, Gruber TA, Klco JM, Baker SD. Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. Leuk Lymphoma. 2017 01;58(1):247-250.
  • Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, Jordan CT, Dong Y. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorg Med Chem. 2016 11 15;24(22):5855-5860.
  • Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD. Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother Pharmacol. 2016 06;77(6):1231-43.
  • Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD. Corrigendum to "Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography" [J. Chromatogr. B 813(1) (2004) 81-88]. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 01;1020:167.